288587-10-0

Basic information

• Product Name: 4-Pyridazinecarbonitrile, 2,3-dihydro-5,6-bis(4-methoxyphenyl)-3-oxo-
• CAS NO: 288587-10-0
• Molecular Formula: C19H15N3O3
• Molecular Weight: 333.346
• Mol File: 288587-10-0.mol

Chemical Properties

• CAS DataBase Reference: 4-Pyridazinecarbonitrile, 2,3-dihydro-5,6-bis(4-methoxyphenyl)-3-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridazinecarbonitrile, 2,3-dihydro-5,6-bis(4-methoxyphenyl)-3-oxo-(288587-10-0)
• EPA Substance Registry System: 4-Pyridazinecarbonitrile, 2,3-dihydro-5,6-bis(4-methoxyphenyl)-3-oxo-(288587-10-0)

Safety Data

• Hazardous Substances Data: 288587-10-0(Hazardous Substances Data)

Upstream product

• 40030-79-3 monohydrazone of 4,4'-dimethoxybenzil 
• 105-56-6 ethyl 2-cyanoacetate 
• 140-87-4 Cyanoacetohydrazide 
• 1226-42-2 1,2-bis(4-methoxyphenyl)-1,2-ethanedione 

Downstream Products

• 102567-33-9 2-(2-Hydroxy-ethyl)-5,6-bis-(4-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carbonitrile 
• 288586-76-5 5,6-bis(4-methoxyphenyl)-2-n-butyl-4-cyano-2H-pyridazin-3-one 
• 288586-80-1 5,6-bis(4-methoxyphenyl)-4-cyano-2-cyclopentylmethyl-2H-pyridazin-3-one 
• 288586-78-7 5,6-bis(4-methoxyphenyl)-4-cyano-2-isobutyl-2H-pyridazin-3-one 

Relevant articles and documents

CCSO nano catalyzed solid phase synthesis of 3-oxo-5,6-disubstituted-2,3-dihydropyridazine-4-carbonitrile

Co-doped Ce0.94Ca0.05Sr0.01O1.94 (CCSO) nano particles have been successfully synthesized by an auto-combustion method and were characterized by XRD, TEM and AFM analyses. The catalytic activity of the nano-catalyst is evaluated by the synthesis of substituted pyridazines from substituted benzil and cyano acetylhydrazide, which have great biological and pharmaceutical interest. Thus, a highly economically efficient one-pot solvent free synthesis of pyridazine was developed, which is promoted by the CCSO nano catalyst. The benefits of the reaction are its very short time (2-4 min) and high yields (90-95%). The method offers a highly convergent, inexpensive, and functionality-tolerable procedure for rapid access to important pyridazine compounds in good yields. This journal is

Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases

Pyrazolopyridazine 1a was identified in a high-throughput screening carried out by BASF Bioresearch Corp. (Worcester, MA) as a potent inhibitor of CDK1/cyclin B and shown to have selectivity for the CDK family. Analogues of the lead compound have been syn